Hims & Hers Health, Inc. is under investigation after the Federal Trade Commission sued the company for allegedly sharing customers' medical data with third-party advertisers like Snap and Meta Platforms. The lawsuit accuses Hims & Hers of deceptive and unlawful privacy practices. Following the news, Hims & Hers' stock price fell more than 14%, prompting a securities litigation law firm to investigate potential investor losses and legal rights. Investors who suffered losses may have claims under federal securities laws and are encouraged to contact the law firm for legal advice.
Hims & Hers Health is under federal investigation and lawsuit for alleged deceptive billing, difficult subscription cancellations, and unauthorized sharing of health data with advertisers. Barclays lowered its price target from $39 to $35, reflecting...
Hims & Hers Health has experienced a significant surge in international revenue, growing over 17-fold year-over-year to $131 million, driven by its acquisition of Eucalyptus and expansion into new markets. The company aims to exceed $600 million in i...
Berger Montague PC has initiated an investigation into Hims & Hers Health, Inc.'s Board of Directors over potential breaches of fiduciary duties. The probe focuses on allegations that the company improperly shared private user health data with advert...
Hims & Hers Health, Inc. is under investigation after the FTC sued the company for allegedly sharing customers' medical information with third-party advertisers like Snap and Meta Platforms. The lawsuit accuses Hims & Hers of deceptive and unlawful p...
